About Bayer’s Commitment in Cardiovascular and Kidney Diseases

Bayer is an innovation leader in the area of cardiovascular diseases, with a long-standing commitment to delivering science for a better life by advancing a portfolio of innovative treatments. The heart and the kidneys are closely linked in health and disease, and Bayer is working in a wide range of therapeutic areas on new treatment approaches for cardiovascular and kidney diseases with high unmet medical needs. The cardiology franchise at Bayer already includes a number of products and several other compounds in various stages of preclinical and clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cardiovascular diseases are treated.


About Chronic Kidney Disease in Type 2 Diabetes

Chronic kidney disease (CKD) is a deadly condition that is underrecognized. CKD is one of the most frequent complications arising from diabetes and is also an independent risk factor of cardiovascular disease. Approximately 40% of all patients with type 2 diabetes develop chronic kidney disease. Despite guideline-directed therapies, patients with CKD and T2D remain at high risk of CKD progression and cardiovascular events. It is estimated that CKD affects more than 160 million people with T2D worldwide. Chronic kidney disease in type 2 diabetes is the main cause of end stage kidney disease which requires dialysis or a kidney transplant to stay alive. MR over-activation is known to trigger detrimental processes (e.g. inflammation and fibrosis) in kidneys and heart in patients with CKD and type 2 diabetes (T2D).



About Heart Failure

Heart failure is a highly prevalent chronic condition: Within the last 8 years, the approximate global prevalence of HF has doubled to over 60 million people. Heart failure is characterized by the progressive decline in the heart’s ability to pump enough blood to meet the body’s needs for blood and oxygen. Risk factors include hypertension, diabetes mellitus, smoking, a past myocardial infarction, and coronary artery disease. Despite advances in therapy and prevention efforts, heart failure remains as malignant as some common cancers. In the U.S. and Europe, 50-60% of hospitalized heart failure patients can be classified as heart failure with reduced ejection fraction (HFrEF). Annually, approximately 30% of patients with symptomatic chronic heart failure will experience worsening of the disease, which is marked by progressive symptoms and/or a recent heart failure event.

Patients with symptomatic chronic heart failure and reduced ejection fraction have a high risk for hospitalization after experiencing symptoms of heart failure requiring outpatient intravenous diuretic treatment or hospitalization. More than half of these patients are rehospitalized within 30 days of discharge due to a worsening event and approximately one in five die within two years. Approximately 2.3 million patients in the EU (1.2 million) and the US (1.1 million) have worsening chronic heart failure.